Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 11/20 | 0.88 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.79 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 2/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938259 | 0.94 | SNCA (1.00) | SNCATRPV1POLBKMT2AABCG2 | |
| SCHEMBL15313137 | 0.91 | SNCA (0.88) | SNCATRPV1 | |
| SCHEMBL9937993 | 0.90 | SNCA (1.00) | SNCATRPV1KMT2A | |
| SCHEMBL9937766 | 0.90 | SNCA (1.00) | SNCATRPV1 | |
| SCHEMBL9936790 | 0.89 | TRPV1 (0.76) | SNCATRPV1POLBKMT2AACHE | |
| SCHEMBL9935439 | 0.88 | SNCA (0.85) | SNCATRPV1POLBKMT2AABCG2 | |
| SCHEMBL9936412 | 0.87 | SNCA (0.84) | SNCATRPV1POLBKMT2AABCG2 | |
| SCHEMBL9937108 | 0.87 | SNCA (1.00) | SNCATRPV1 | |
| SCHEMBL15313150 | 0.86 | SNCA (1.00) | SNCAPOLBKMT2A | |
| SCHEMBL15313123 | 0.84 | SNCA (1.00) | SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | SNCA 1/4885TRPV1 2864/4885POLB 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.